Prescribing Information | JAKAFI® (ruxolitinib) Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it
Myelofibrosis (MF) Jakafi® (ruxolitinib) | Jakafi. com Find information about myelofibrosis (MF) and Jakafi® (ruxolitinib), the first FDA-approved prescription medicine for adults with intermediate or high-risk myelofibrosis
Polycythemia Vera (PV) Jakafi® (ruxolitinib) | Jakafi. com Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it
What is Jakafi® (ruxolitinib)? Learn about Jakafi, a prescription medicine available as a pill Jakafi is used to treat adults with intermediate or high-risk myelofibrosis (MF)
Jakafi Indications and Usage Jakafi ® (ruxolitinib) is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyur
Polycythemia Vera Medication – Jakafi Benefits Side Effects Read about the benefits and possible side effects of taking Jakafi® (ruxolitinib) Jakafi is for adults with polycythemia vera (PV) who had already taken hydroxyurea and it did not work well enough or they could not tolerate it